CD19 Carty and Hypogammaglobininemia

In patients who receive CD19 carty, the main hypogammaglobininemia problem is an overall low-cereomygg level. This gets exaggerated after carty, reaches 70% in the first three months and decreases to only to 41% at the one-year mark. On the other side, in BCMA carty, pathogen-specific IgG levels are significantly lower than after CD19 Carty. The reason for this may be due to the fact that BCMA is expressed on the late-stage memory B cells and the long-delerved plasma cells. It's very important for the survival of those long-delivery plasma cells.